07/11/05
The Hauppauge, New York facility of A&Z Pharmaceutical Inc. was inspected by the FDA. The inspection result was satisfactory and there was no 483 issued. This marked the company’s long-term commitment to cGMP compliance.

06/13/05
The company decided to launch SoyCal® in China. It is a dietary supplement supporting the health of menopausal women. This product would be mainly distributed in retail market.

05/16/05
The company’s new product Calcium Polycarbophil 625mg caplet, a generic version of the brand product “FiberCon”, was introduced to market.

04/11/05
In order to meet the increasing demands, the generic Ibuprofen 200mg tablets, comparable to the brand “Advil”, were offered to retail customers for the first time.

02/25/05
Gained access to the new 150,000 sq. ft. manufacturing facility of Anshi Pharmaceutical (Zhongshan) Inc. located in China. It is dedicated to supporting A&Z’s business not only in China but around the world.